These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 12190331)

  • 41. Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Kitazawa F; Fuchida SI; Kado Y; Ueda K; Kokufu T; Okano A; Hatsuse M; Murakami S; Nakayama Y; Takara K; Shimazaki C
    Ann Transplant; 2017 Sep; 22():575-580. PubMed ID: 28947731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacokinetic drug interaction between miconazole mucoadhesive tablet and tacrolimus: About 3 case-reports in transplant patients].
    Lepelley M; Logerot S; Fonrose X; Villier C
    Therapie; 2017 Sep; 72(4):475-482. PubMed ID: 28214069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of P-glycoprotein in pharmacokinetics: clinical implications.
    Lin JH; Yamazaki M
    Clin Pharmacokinet; 2003; 42(1):59-98. PubMed ID: 12489979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insights into oral bioavailability enhancement of therapeutic herbal constituents by cytochrome P450 3A inhibition.
    Chen J; Liu J; Huang Y; Li R; Ma C; Zhang B; Wu F; Yu W; Zuo X; Liang Y; Wang Q
    Drug Metab Rev; 2021 Nov; 53(4):491-507. PubMed ID: 33905669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validation of methods to study the distribution and protein binding of tacrolimus in human blood.
    Zahir H; Nand RA; Brown KF; Tattam BN; McLachlan AJ
    J Pharmacol Toxicol Methods; 2001; 46(1):27-35. PubMed ID: 12164257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery.
    Hebert MF
    Adv Drug Deliv Rev; 1997 Sep; 27(2-3):201-214. PubMed ID: 10837558
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A follow-up report on potential drug interactions with clementines: Two single case experiments show no effect on CYP3A-dependent midazolam clearance.
    Hohmann N; Mikus G; Haefeli WE; Schwenger V; Gattuso G; Barreca D; Weiss J
    Eur J Pharm Sci; 2019 May; 133():54-58. PubMed ID: 30905614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P-glycoprotein and drug therapy in organ transplantation.
    Lo A; Burckart GJ
    J Clin Pharmacol; 1999 Oct; 39(10):995-1005. PubMed ID: 10516933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunosuppressive drug therapy--biopharmaceutical challenges and remedies.
    Khan S; Khan S; Baboota S; Ali J
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1333-49. PubMed ID: 25642742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy.
    Warrington JS; Shaw LM
    Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):487-503. PubMed ID: 16863457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral absorption of the HIV protease inhibitors: a current update.
    Williams GC; Sinko PJ
    Adv Drug Deliv Rev; 1999 Oct; 39(1-3):211-238. PubMed ID: 10837775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Marked decrease of tacrolimus blood concentration caused by compound Chinese herbal granules in a patient with refractory nephrotic syndrome.
    Yang P; He F; Tan M; Zhong F; Liao X; Li Y; Deng H; Mo X
    J Clin Pharm Ther; 2021 Feb; 46(1):215-218. PubMed ID: 32930420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU.
    Spriet I; Meersseman W; de Hoon J; von Winckelmann S; Wilmer A; Willems L
    Intensive Care Med; 2009 Apr; 35(4):603-12. PubMed ID: 19132344
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food.
    Miedziaszczyk M; Bajon A; Jakielska E; Primke M; Sikora J; Skowrońska D; Idasiak-Piechocka I
    Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297591
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formulation strategies for drug delivery of tacrolimus: An overview.
    Patel P; Patel H; Panchal S; Mehta T
    Int J Pharm Investig; 2012 Oct; 2(4):169-75. PubMed ID: 23580932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How important are gender differences in pharmacokinetics?
    Meibohm B; Beierle I; Derendorf H
    Clin Pharmacokinet; 2002; 41(5):329-42. PubMed ID: 12036391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of Legalized Marijuana.
    Hauser N; Sahai T; Richards R; Roberts T
    Case Rep Transplant; 2016; 2016():4028492. PubMed ID: 27595035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Valspodar: current status and perspectives.
    Loor F
    Expert Opin Investig Drugs; 1999 Jun; 8(6):807-35. PubMed ID: 15992133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating the clinical significance of drug interactions: a systematic approach.
    Callahan AM; Marangell LB; Ketter TA
    Harv Rev Psychiatry; 1996; 4(3):153-8. PubMed ID: 9384988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinical significance of drug interactions between dermatological and psychoactive medications.
    Frew JW
    Dermatol Ther; 2014; 27(1):1-11. PubMed ID: 24502302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.